TREMFYA® (guselkumab) data vs competitor in Moderate to Severe Plaque Psoriasis | TREMFYA® (guselkumab) HCP

TREMFYA® EFFICACY DATA IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS
DATA vs HUMIRA® (adalimumab)

Superior Skin Clearance vs Humira®: PASI 75* at Week 161,2

View Study Designs

VOYAGE 1: MAJOR SECONDARY ENDPOINT AT WEEK 16 (NORTH AMERICAN ANALYSIS)

The same patients may not have responded at each time point.

PASI 75 at Weeks 24 and 48 were prespecified exploratory endpoints that were not adjusted for multiplicity; P values were considered nominal.

VOYAGE 2: MAJOR SECONDARY ENDPOINT AT WEEK 16 (NORTH AMERICAN ANALYSIS)

§P<0.001 vs Humira®.

Based on the results of an analysis of 38 North American sites (United States=27, Canada=11) from VOYAGE 1 and 41 North American ‭sites (United States=31, Canada=10) from VOYAGE 2 that used US-licensed Humira®.‬‬‬‬‬‬‬‬‬‬‬

*PASI 75=Proportion of patients who achieved 75% or more reduction (or improvement) in PASI score from baseline.

TREMFYA®—Consistent PASI 90 Response Rates That Were Superior to Humira® at Weeks 16, 24, and 481,2

View Study Designs

VOYAGE 1: MAJOR SECONDARY ENDPOINTS AT WEEKS 16, 24, AND 48 (NORTH AMERICAN ANALYSIS)

The same patients may not have responded at each time point.

VOYAGE 2: MAJOR SECONDARY ENDPOINTS AT WEEKS 16 AND 24 (NORTH AMERICAN ANALYSIS)

P<0.001 vs Humira®.

P=0.003 vs Humira®.

Based on the results of an analysis of 38 North American sites (United States=27, Canada=11) from VOYAGE 1 and 41 North American ‭sites (United States=31, Canada=10) from VOYAGE 2 that used US-licensed Humira®.‬‬‬‬‬‬‬‬‬‬‬

TREMFYA®—Consistent IGA 0/1 Response Rates That Were Superior to Humira® at Weeks 16, 24, and 481,2

View Study Designs

VOYAGE 1: MAJOR SECONDARY ENDPOINTS AT WEEKS 16, 24, AND 48 (NORTH AMERICAN ANALYSIS)

The same patients may not have responded at each time point.

VOYAGE 2: MAJOR SECONDARY ENDPOINTS AT WEEKS 16 AND 24 (NORTH AMERICAN ANALYSIS)

P<0.027 vs Humira®.

P=0.005 vs Humira®.

Based on the results of an analysis of 38 North American sites (United States=27, Canada=11) from VOYAGE 1 and 41 North American ‭sites (United States=31, Canada=10) from VOYAGE 2 that used US-licensed Humira®.‬‬‬‬‬‬‬‬‬‬‬

Nearly Twice as Many Patients Were Rated as Cleared (IGA 0) With TREMFYA® vs Humira® at Weeks 24 and 481,2

View Study Designs

VOYAGE 1: MAJOR SECONDARY ENDPOINTS AT WEEKS 24 AND 48 (NORTH AMERICAN ANALYSIS)

The same patients may not have responded at each time point.

VOYAGE 2: MAJOR SECONDARY ENDPOINT AT WEEK 24 (NORTH AMERICAN ANALYSIS)

P=0.005 vs Humira®.

Based on the results of an analysis of 38 North American sites (United States=27, Canada=11) from VOYAGE 1 and 41 North American ‭sites (United States=31, Canada=10) from VOYAGE 2 that used US-licensed Humira®.‬‬‬‬‬‬‬‬‬‬‬

PASI 100* Response Rates at Weeks 24 and 48‬‬1,2‬‬‬‬‬‬‬‬‬

View Study Designs

VOYAGE 1: PRESPECIFIED EXPLORATORY ENDPOINT AT WEEKS 24 AND 48 (NORTH AMERICAN ANALYSIS)

PASI 100 was a prespecified exploratory endpoint that was not adjusted for multiplicity; P values were considered nominal.

The same patients may not have responded at each time point.

Based on the results of an analysis of 38 North American sites (United States=27, Canada=11) from VOYAGE 1 that used US-licensed Humira®.

*PASI 100=Proportion of patients who achieved 100% reduction (or improvement) in PASI score from baseline.‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬

Humira® is a registered trademark of AbbVie Inc.

References: 1. TREMFYA® (guselkumab) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc. 2. Data on file. Janssen Biotech, Inc.